Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation.
OBJECTIVE
Total-body irradiation (TBI) has an important role in patients undergoing hematopoietic cell transplantation (HCT), but is associated with significant toxicities. Targeted TBI using helical tomotherapy results in reduced doses to normal organs, which predicts for reduced toxicities compared with standard TBI.


METHODS
Thirteen patients with multiple myeloma were treated in an autologous tandem transplantation Phase I trial with high-dose melphalan, followed 6 weeks later by total-marrow irradiation (TMI) to skeletal bone. Dose levels were 10, 12, 14, and 16 Gy at 2 Gy daily/twice daily. In a separate allogeneic HCT trial, 8 patients (5 with acute myelogenous leukemia, 1 with acute lymphoblastic leukemia, 1 with non-Hodgkin's lymphoma, and 1 with multiple myeloma) were treated with TMI plus total lymphoid irradiation plus splenic radiotherapy to 12 Gy (1.5 Gy twice daily) combined with fludarabine/melphalan.


RESULTS
For the 13 patients in the tandem autologous HCT trial, median age was 54 years (range, 42-66 years). Median organ doses were 15-65% that of the gross target volume dose. Primarily Grades 1-2 acute toxicities were observed. Six patients reported no vomiting; 9 patients, no mucositis; 6 patients, no fatigue; and 8 patients, no diarrhea. For the 8 patients in the allogeneic HCT trial, median age was 52 years (range, 24-61 years). Grades 2-3 nausea, vomiting, mucositis, and diarrhea were observed. In both trials, no Grade 4 nonhematologic toxicity was observed, and all patients underwent successful engraftment.


CONCLUSIONS
This study shows that TMI using helical tomotherapy is clinically feasible. The reduced acute toxicities observed compare favorably with those seen with standard TBI. Initial results are encouraging and warrant further evaluation as a method to dose escalate with acceptable toxicity or to offer TBI-containing regimens to patients unable to tolerate standard approaches.
Wong
Jeffrey Y C
JY
Division of Radiation Oncology and Radiation Research, City of Hope Cancer Center, Duarte, CA, USA.
Rosenthal
Joseph
J
Liu
An
A
Schultheiss
Timothy
T
Forman
Stephen
S
Somlo
George
G
D000328:Adult; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000000981:diagnostic imaging / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000000981:diagnostic imaging / Q000628:therapy*; D011879:Radiotherapy Dosage; D020266:Radiotherapy, Conformal / Q000379:methods*; D013813:Therapy, Computer-Assisted / Q000379:methods; D014057:Tomography, X-Ray Computed / Q000379:methods*; D016896:Treatment Outcome; D014916:Whole-Body Irradiation / Q000379:methods*
Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S74-82
16979445
Biol Blood Marrow Transplant. 2006 Mar;12(3):306-15
16503500
Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):876-84
16199317
Blood. 2002 Feb 1;99(3):731-5
11806971
Semin Radiat Oncol. 1999 Jan;9(1):108-17
10196402
Blood. 1998 Aug 15;92(4):1455-6
9694737
Cancer. 1975 Sep;36(3):842-54
1182674
Int J Radiat Oncol Biol Phys. 1987 Jul;13(7):1065-9
3298176
Blood. 2003 Oct 1;102(7):2684-91
12730103
Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):227-34
16169680
Bone Marrow Transplant. 2003 Sep;32(6):543-8
12953124
Radiother Oncol. 1985 Dec;4(4):341-51
3909241
Blood. 1994 May 1;83(9):2723-30
8167351
Bone Marrow Transplant. 2002 May;29(10):807-16
12058230
Ann Intern Med. 1986 Feb;104(2):168-75
3511812
Bone Marrow Transplant. 2006 Mar;37(5):463-7
16435013
J Clin Oncol. 1988 Oct;6(10):1562-8
3049951
Int J Radiat Oncol Biol Phys. 1995 Jan 1;31(1):119-28
7995742
Blood. 1991 Apr 15;77(8):1660-5
2015394
Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1259-67
17336225
Blood. 2001 Jun 1;97(11):3669-71
11392326